PharmaEssentia (6446.TW) stock: key figures, P/E, revenue and dividend
Health Care · Taiwan · ISIN TW0006446008
PharmaEssentia financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 9.73 bn TWD | 15.63 bn TWD |
| Gross profit | 8.56 bn TWD | 13.68 bn TWD |
| Operating income | 1.74 bn TWD | 4.93 bn TWD |
| EBIT | 3.02 bn TWD | 5.01 bn TWD |
| Net income | 2.97 bn TWD | 5.05 bn TWD |
| Diluted EPS – continuing operations | 8.17 TWD | 13.64 TWD |
Full history since 2010, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About PharmaEssentia
PharmaEssentia Corporation, a biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan. Its products include BESREMi, an interferon therapy indicated for polycythemia vera, essential thrombocythemia, PMF, and adult T-cell leukemias. The company also develops Ropeg + anti PD-1; PEG-IL-2 (P11838); PEG-Cytokines; PD-1-IL-2v; ADC; ADCS; NY-ESO-1 TCR-T; and Novel TCR-T for the treatment of solid tumor and immunology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.
More stocks
- Performance Food Group Co (PFGC)
- SUN COMMUNITIES INC (SUI)
- Nippon Sanso Holdings Corp (4091.T)
- NEUROCRINE BIOSCIENCES INC (NBIX)
- HUAQIN TECHNOLOGY LTD A (603296.SS)
- Kinsus Interconnect Technology Corp (3189.TW)
- Zhongjin Gold Corp Ltd (600489.SS)
- Guangdong Wens Foodstuff Group Co Ltd (300498.SZ)
- Betsson AB (BETS B.ST)
- Metro Inc (MRU.TO)
- Unibail-Rodamco-Westfield SE (URW.PA)
- Ascendis Pharma AS (ASND)
Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.